351. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
- Author
-
Hegde GV, de la Cruz C, Giltnane JM, Crocker L, Venkatanarayan A, Schaefer G, Dunlap D, Hoeck JD, Piskol R, Gnad F, Modrusan Z, de Sauvage FJ, Siebel CW, and Jackson EL
- Subjects
- Animals, Carcinoma, Squamous Cell genetics, Cell Line, Tumor, Cell Proliferation, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Mice, Nude, Receptor, ErbB-3 metabolism, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Cell Differentiation, Neuregulin-1 metabolism, Transcription Factors metabolism, Tumor Suppressor Proteins metabolism
- Abstract
Squamous cell carcinomas (SCCs) account for the majority of cancer mortalities. Although TP63 is an established lineage-survival oncogene in SCCs, therapeutic strategies have not been developed to target TP63 or it's downstream effectors. In this study we demonstrate that TP63 directly regulates NRG1 expression in human SCC cell lines and that NRG1 is a critical component of the TP63 transcriptional program. Notably, we show that squamous tumors are dependent NRG1 signaling in vivo, in both genetically engineered mouse models and human xenograft models, and demonstrate that inhibition of NRG1 induces keratinization and terminal squamous differentiation of tumor cells, blocking proliferation and inhibiting tumor growth. Together, our findings identify a lineage-specific function of NRG1 in SCCs of diverse anatomic origin., Competing Interests: GH, Cd, JG, LC, AV, GS, DD, JH, RP, FG, ZM, Fd, CS, EJ employee of Genentech Inc at the time of participation in this study, (© 2019, Hegde et al.)
- Published
- 2019
- Full Text
- View/download PDF